Researchers from North Carolina State University have synthesized an analog of lipoxazolidinone A, a small molecule that is effective against drug-resistant bacteria such as MRSA. This molecule, a new synthetic compound inspired by a natural product, could be a useful chemical tool for studying other Gram-positive infections and may have implications for future drug creation.
Lipoxazolidinone A is a natural product which had been previously isolated from bacteria living in marine sediments. It is a secondary metabolite – a small molecule produced by the bacteria that isn’t key to its survival but is produced for a secondary purpose, like defense. When lipoxazolidinone A was initially isolated, researchers noted that it seemed effective against Gram-positive bacteria, like MRSA.
NC State chemist Joshua Pierce aimed to confirm those original findings and understand how the molecule’s structure correlated to its function; in short, he wanted to recreate the molecule to see what portions were directly responsible for its anti-microbial properties and then potentially improve upon that structure.
Pierce, along with current NC State graduate student Kaylib Robinson and former students Jonathan Mills and Troy Zehnder, used novel chemical tools to synthesize lipoxazolidinone A in the lab. They were able to confirm that its chemical structure matched what the initial researchers had indicated, then they worked to identify the portion of the molecule that was responsible for the activity against Gram-positive bacteria. Their result was a compound with improved potency, JJM-35.
They tested JJM-35 against a panel of resistant and non-resistant bacteria. When tested against MRSA in vitro, they found that the synthesized molecule was up to 50 times more effective than the natural product against several bacterial strains. Additionally, they found that the molecule was often more effective against resistant bacterial strains than it was against nonresistant strains.
“An exciting additional aspect of this work was that we identified that these molecules may function by inhibiting multiple biosynthetic pathways directly or indirectly,” says Pierce. “This means that bacteria may have difficulty developing resistance to potential drugs developed from these molecules.”
While more work is needed, Pierce hopes that JJM-35 and similar compounds can be used as tools to study other Gram-positive bacteria and provide a platform for the development of a novel class of anti-infective agents.
“At this point, we have a chemical scaffold – a starting piece of the puzzle. We know that this piece is effective, and so right now all efforts are focused on evaluating the properties of these molecules and their in vivo efficacy,” says Pierce. “The hope is that we can build upon this scaffold to create drugs that are effective against MRSA and other resistant bacteria at a time of dire need for antimicrobial development while also increasing the spectrum of activity.”
The Latest on: Antimicrobial development
via Google News
The Latest on: Antimicrobial development
- Chemical in soaps, hand sanitizers tied to osteoporosison June 26, 2019 at 1:09 pm
Triclosan has been widely used for years as an antimicrobial agent in consumer goods and personal ... production of thyroid hormones and estrogen that interrupt normal skeletal development and ... […]
- Pharmacometrics Applications can Revamp Clinical Development!on June 26, 2019 at 6:05 am
FREMONT, CA: With the emergence of anti-infective resistance characteristics in the past few years, much focus has been laid to develop advanced synthetic anti-infectives for establishing effective ... […]
- Antimicrobial Plastics Market 2019 Global Trends, Market Share, Industry Size, Growth, Opportunities, and Market Forecast to 2025on June 26, 2019 at 5:54 am
In addition, the antimicrobial operator should likewise have the option to move to the plastic surface to counteract microbial development. Among them, organic antibacterial operators are broadly ... […]
- Sanara MedTech Inc. Announces Expanded Line of Credit, Launch of BIAKOS(TM) Antimicrobial Skin & Wound Cleanser and Approval of Stock Purchase Programon June 25, 2019 at 5:42 am
Shawn Bowman, President, Wound Care Division, stated, "BIAKŌS ™ Antimicrobial Skin & Wound Cleanser is ... to the future impact on the Company's results from new products in development and any other ... […]
- Antimicrobial Drug Resistance: A Global Disaster in makingon June 24, 2019 at 12:03 pm
Misuse and overuse of existing antimicrobials in humans, animals and plants are accelerating development and spread of antimicrobial resistance, for example using antibiotics for viral infections such ... […]
- Antimicrobial protein found in echidna milkon June 24, 2019 at 2:36 am
A recent study 1 has identified a novel antimicrobial protein (AMP ... solely dependent on its mother’s milk for development. The study is a collaborative effort between researchers at the ... […]
- New commitments in the fight against antimicrobial resistanceon June 22, 2019 at 4:22 pm
The awarded funding will support the development of a state-of-the-art, virtual ‘open access’ centre that will link health outcomes and prescribing data. This technology, led by Public Health England ... […]
- Antimicrobial Therapeutics Market to Grow by USD 22.78 Billion During 2019-2023 | Technavioon June 21, 2019 at 3:01 am
the development of the pipeline drugs will positively impact the growth of this segment during the forecast period,” says a senior research analyst at Technavio. Speak to Research Expert ... […]
- New Multi-Partner Trust Fund launched to combat Antimicrobial Resistance globallyon June 19, 2019 at 8:50 am
"This new Trust Fund signals an important new commitment to combat antimicrobial resistance. AMR is a serious challenge to reaching universal health coverage and a threat to achievement of the ... […]
via Bing News